

11-1-2004

The 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductases

Jon A. Friesen

Illinois State University, jfrieese@ilstu.edu

Victor W. Rodwell

Purdue University, vrodwell@purdue.edu

Follow this and additional works at: <http://docs.lib.purdue.edu/biochempubs>

Recommended Citation

Friesen, Jon A. and Rodwell, Victor W., "The 3-Hydroxy-3-Methylglutaryl Coenzyme-A (HMG-CoA) Reductases" (2004).
Department of Biochemistry Faculty Publications. Paper 8.
<http://dx.doi.org/10.1186/gb-2004-5-11-248>

This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact epubs@purdue.edu for additional information.

Protein family review

The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases

Jon A Friesen* and Victor W Rodwell†

Addresses: *Department of Chemistry, Illinois State University, Normal, IL 61790-4160, USA. †Department of Biochemistry, Purdue University, 175 South University Street, West Lafayette, IN 47907-2063, USA.

Correspondence: Jon A Friesen. E-mail: jfrieese@ilstu.edu

Published: 1 November 2004

Genome Biology 2004, **5**:248

The electronic version of this article is the complete one and can be found online at <http://genomebiology.com/2004/5/11/248>

© 2004 BioMed Central Ltd

Summary

The enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyzes the conversion of HMG-CoA to mevalonate, a four-electron oxidoreduction that is the rate-limiting step in the synthesis of cholesterol and other isoprenoids. The enzyme is found in eukaryotes and prokaryotes; and phylogenetic analysis has revealed two classes of HMG-CoA reductase, the Class I enzymes of eukaryotes and some archaea and the Class II enzymes of eubacteria and certain other archaea. Three-dimensional structures of the catalytic domain of HMG-CoA reductases from humans and from the bacterium *Pseudomonas mevalonii*, in conjunction with site-directed mutagenesis studies, have revealed details of the mechanism of catalysis. The reaction catalyzed by human HMG-CoA reductase is a target for anti-hypercholesterolemic drugs (statins), which are intended to lower cholesterol levels in serum. Eukaryotic forms of the enzyme are anchored to the endoplasmic reticulum, whereas the prokaryotic enzymes are soluble. Probably because of its critical role in cellular cholesterol homeostasis, mammalian HMG-CoA reductase is extensively regulated at the transcriptional, translational, and post-translational levels.

Gene organization and evolutionary history


The human *hmgr* gene that encodes the single human HMG-CoA reductase is located on chromosome 5, map location 5q13.3-5q14, and is over 24.8 kilobases (kb) long. The 20 exons of the 4,475-nucleotide transcript, which range in size from 27 to 1,813 base-pairs, encode the membrane-anchor domain (exons 2-10), a flexible linker region (exons 10 and 11), and the catalytic domain (exons 11-20) of the resulting 888-residue polypeptide (Figure 1).

Genome sequencing has identified *hmgr* genes in organisms from all three domains of life, and over 150 HMGR sequences are recorded in public databases. Higher animals, archaea, and eubacteria have only a single *hmgr* gene, although the lobster has both a soluble and a membrane-associated isozyme, both of which are encoded by a single gene). By contrast, plants, which use both HMGR-dependent and HMGR-independent pathways to synthesize isoprenoids,

have multiple HMGR isozymes that appear to have arisen by gene duplication and subsequent sequence divergence [1]. Yeast has two HMGR isozymes derived from two different genes (*hmgr-1* and *hmgr-2*). Comparison of amino-acid sequences and phylogenetic analysis reveals two classes of HMGR, the Class I enzymes of eukaryotes and some archaea and the Class II enzymes of certain eubacteria and archaea, suggesting evolutionary divergence between the two classes (Figure 2, Table 1) [2,3]. The catalytic domain is highly conserved in eukaryotes, but the membrane-anchor domain (consisting of between two and eight membrane-spanning helices) is poorly conserved, and the HMGRs of archaea and of certain eubacteria lack a membrane-anchor domain.

Characteristic structural features

The HMGRs of different organisms are multimers of a species-specific number of identical monomers. High-resolution

**Figure 1**

Schematic representation of the human *hmgr* gene and the human HMGR_H and *P. mevalonii* HMGR_P proteins. **(a)** The exon-intron structure of the human *hmgr* gene, which extends from position 74717172 to position 74741998 of the human genome; positions refer to the Ensembl Transcript ID for the human *hmgr* gene (ENST00000287936 [22]). The numbers indicate the start and end of each exon and intron and refer to the position in the human genome sequence, omitting the first three digits (747); exons are indicated as filled boxes. Exon 1 is an untranslated region (UTR), as are the last 1,758 nucleotides of exon 20. The exons encoding the membrane-anchor domain, a flexible linker region, and the catalytic domain are indicated below the gene structure. **(b)** Human HMGR protein (HMGR_H) is comprised of three domains: the membrane-anchor domain, a linker domain, and a catalytic domain; within the catalytic domain subdomains have been defined. The N domain connects the L domain to the linker domain; the L domain contains an HMG-CoA binding region; and the S domain functions to bind NADP(H). The *cis*-loop (indicated by an asterisk), a region present only in HMGR_H but not HMGR_P, connects the HMG-CoA-binding region with the NADPH-binding region. **(c)** The HMGR_P protein does not contain the membrane-anchor domain or the linker domain but has a catalytic domain containing a large domain with an HMG-CoA binding region, and a small, NAD(H)-binding domain. The active site of HMG-CoA reductase is present at the homodimer interface between one monomer that binds the nicotinamide dinucleotide and a second monomer that binds HMG-CoA. The numbers underneath the diagrams in (b,c) denote amino acids (in the single-letter amino-acid code) that are implicated in catalysis; S872 of HMGR_H is reversibly phosphorylated. At the extreme carboxyl terminus of each enzyme is a flap domain (approximately 50 amino acids in HMGR_P and 25-30 amino acids in HMGR_H) that closes over the active site during catalysis; the flap domain is indicated by shading in (b,c).

crystal structures have been solved for the Class I human enzyme (HMGR_H) [4,5] and for the Class II enzyme of *Pseudomonas mevalonii* (HMGR_P) [6,7], including protein forms bound to either the HMG-CoA substrate or the coenzyme (NADH or NADPH) or both, or bound to statin drugs, which are potent competitive inhibitors of HMGR activity and thus lower cholesterol levels in the blood [8,9]. As reviewed in detail by Istvan [10], structural comparisons reveal both similarities and significant differences between the two classes of enzyme. The human HMGR has three major domains (catalytic, linker and anchor), whereas the *P. mevalonii* HMGR has only the catalytic domain (Figure 1).

Both HMGR_H and HMGR_P have a dimeric active site with residues contributed by each monomer, and a non-Rossmann-type coenzyme-binding site (a three-dimensional structural fold that contains a nucleotide-binding motif and is found in many enzymes that use the dinucleotides NADH and NADPH for catalysis). The core regions containing the catalytic domains of the two enzymes have similar folds. Despite differences in amino-acid sequence and overall architecture, functionally similar residues participate in the binding of coenzyme A by the two enzymes, and the position and orientation of four key catalytic residues (glutamate, lysine, aspartate and histidine) is conserved in both classes of HMGR.




Figure 2

A phylogenetic tree of HMGRs. The tree includes 98 selected organisms that have *hmgr* genes; for plants, which have multiple isoforms, only isoform I of each species is included in the tree. Roman numerals indicate the division of the family into two classes [2,3]. Phylogenetic analysis was performed using aligned amino-acid sequences of HMGR catalytic domains; membrane anchor domains were excluded from analysis. Amino-acid sequence alignments were generated using ClustalW [23] and the phylogenetic tree constructed with TreeTop [24] using the cluster algorithm with PHYLIP tree-type output. Full species names and GenBank accession numbers of the sequences used are provided in Table 1.

Unlike the central cores, the amino- and carboxy-terminal regions of the catalytic domains show little similarity between the human and *P. mevalonii* HMGR structures. The active site of HMG-CoA reductase is at the interface of the homodimer between one monomer that binds the nicotinamide dinucleotide and a second monomer that binds the HMG-CoA. In human HMGR, the catalytic lysine is found on the monomer that binds the HMG-CoA and comes from the so-called *cis*-loop (a section that connects the HMG-CoA-binding region with the NADPH-binding region). In contrast, the

P. mevalonii HMGR lacks the *cis*-loop and the catalytic lysine is contributed by the monomer that binds the nicotinamide dinucleotide. HMGR_p crystallizes as a trimer of dimers (which are composed of identical subunits), but HMGR_H crystallizes as a tetramer (of identical units). HMGR_p uses NADH as a coenzyme, whereas HMGR_H uses NADPH, but mutation to alanine of the aspartyl residue of HMGR_p that normally blocks the binding of NADPH can allow NADPH to serve - albeit poorly - as the coenzyme for HMGR_p. A 180° difference in the orientation of the nicotinamide ring of the coenzyme suggests that

Table 1**Details of the sequences used for the phylogenetic tree in Figure 2**

Organism name*	Kingdom	Accession number
<i>Mus musculus</i> (mouse)	Eukaryote	XM_127496
<i>Mesocricetus auratus</i> (hamster)	Eukaryote	X00494
<i>Rattus norvegicus</i> (rat)	Eukaryote	BC064654
<i>Homo sapiens</i> (human)	Eukaryote	NM_000859
<i>Gallus gallus</i> (chicken)	Eukaryote	AB109635
<i>Xenopus laevis</i> (frog)	Eukaryote	M29258
<i>Drosophila melanogaster</i> (fruit fly)	Eukaryote	NM_206548
<i>Homarus americanus</i> (lobster)	Eukaryote	AY292877
<i>Blattella germanica</i> (cockroach)	Eukaryote	X70034
<i>Dendroctonus jeffreyi</i> (Jeffrey pine beetle)	Eukaryote	AF159136
<i>Ips pini</i> (bark beetle)	Eukaryote	AF304440
<i>Ips paraconfusus</i> (bark beetle)	Eukaryote	AF071750
<i>Raphanus sativus</i> (radish)	Eukaryote	X68651
<i>Arabidopsis thaliana</i> (thale-cress)	Eukaryote	NM_106299
<i>Oryza sativa</i> (rice)	Eukaryote	AF110382
<i>Lycopersicon esculentum</i> (tomato)	Eukaryote	AAL16927
<i>Nicotinia tabacum</i> (tobacco)	Eukaryote	AF004232
<i>Cucumis melo</i> (muskmelon)	Eukaryote	AB021862
<i>Hevea brasiliensis</i> (rubber tree)	Eukaryote	X54659
<i>Pisum sativum</i> (pea)	Eukaryote	AF303583
<i>Solanum tuberosum</i> (potato)	Eukaryote	L01400
<i>Tagetes erecta</i> (African marigold)	Eukaryote	AF034760
<i>Catharanthus roseus</i> (Madagascar periwinkle)	Eukaryote	M96068
<i>Artemisia annua</i> (wormwood)	Eukaryote	AF142473
<i>Gossypium hirsutum</i> (cotton)	Eukaryote	AF038046
<i>Taxus x media</i> (yew)	Eukaryote	AY277740
<i>Andrographis paniculata</i> (Indian herb)	Eukaryote	AY254389
<i>Malus x domestica</i> (apple)	Eukaryote	AY043490
<i>Capsicum annuum</i> (pepper)	Eukaryote	AF110383
<i>Campthotheca acuminata</i>	Eukaryote	U72145
<i>Saccharomyces cerevisiae</i> (baker's yeast)	Eukaryote	M22002
<i>Schizosaccharomyces pombe</i> (fission yeast)	Eukaryote	CAB57937
<i>Candida utilis</i>	Eukaryote	AB012603
<i>Trypanosoma cruzi</i> (trypanosome)	Eukaryote	L78791
<i>Schistosoma mansoni</i>	Eukaryote	M27294
<i>Leishmania major</i> (trypanosome)	Eukaryote	AF155593
<i>Dictyostelium discoideum</i>	Eukaryote	L19349
<i>Caenorhabditis elegans</i>	Eukaryote	NM_066225
<i>Strongylocentrotus purpuratus</i> (sea urchin)	Eukaryote	NM_214559
<i>Dicentrarchus labrax</i> (European sea bass)	Eukaryote	AY424801
<i>Penicillium citrinum</i>	Eukaryote	AB072893
<i>Ustilago maydis</i>	Eukaryote	XM_400629
<i>Eremothecium gossypii</i>	Eukaryote	NM_210364
<i>Gibberella zeae</i>	Eukaryote	XM_389373
<i>Gibberella fujikuroi</i>	Eukaryote	X94307
<i>Sphaceloma manihoticola</i>	Eukaryote	X94308
<i>Aspergillus nidulans</i>	Eukaryote	EAA60025
<i>Neurospora crassa</i>	Eukaryote	XM_324891
<i>Phycomyces blakesleeanus</i>	Eukaryote	X58371
<i>Archaeoglobus fulgidus</i>	Archaea	NC_000917
<i>Sulfolobus solfataricus</i>	Archaea	U95360
<i>Oceanobacillus ihheyensis</i>	Archaea	NC_004193
<i>Thermoplasma volcanium</i>	Archaea	BAB60335
<i>Halobacterium</i> sp	Archaea	AAG20075
<i>Methanosarcina mazei</i>	Archaea	AAM30031
<i>Haloarcula hispanica</i>	Archaea	AF123438
<i>Thermoplasma acidophilum</i>	Archaea	CAC11548
<i>Picrophilus torridus</i>	Archaea	AE017261
<i>Archaeoglobus veneficus</i>	Archaea	AJ299204

Table 1 (continued)

Organism name	Kingdom	Accession number
<i>Ferroglobus placidus</i>	Archaea	AJ299206
<i>Archaeoglobus profundus</i>	Archaea	AJ299205
<i>Archaeoglobus lithotrophicus</i>	Archaea	AJ299203
<i>Haloferax volcanii</i>	Archaea	M83531
<i>Pyrococcus furiosus</i>	Archaea	AAL81972
<i>Pyrococcus abyssi</i>	Archaea	AJ248284
<i>Methanococcus maripaludis</i>	Archaea	CAF29643
<i>Methanocaldococcus jannaschii</i>	Archaea	AAB98699
<i>Methanosarcina acetivorans</i>	Archaea	AAM06446
<i>Methanopyrus kandleri</i>	Archaea	AAM01570
<i>Sulfolobus tokodaii</i>	Archaea	AP000986
<i>Aeropyrum pernix</i>	Archaea	AP000062
<i>Methanothermobacter thermautotrophicus</i>	Archaea	AAB85068
<i>Pyrobaculum aerophilum</i>	Archaea	AAL64009
<i>Bdellovibrio bacteriovorus</i>	Eubacteria	BX842650
<i>Lactobacillus plantarum</i>	Eubacteria	AL935253
<i>Streptococcus agalactiae</i>	Eubacteria	CAD47046
<i>Lactococcus lactis</i>	Eubacteria	AE006387
<i>Vibrio cholerae</i>	Eubacteria	AAF96622
<i>Vibrio vulnificus</i>	Eubacteria	AAO07090
<i>Vibrio parahaemolyticus</i>	Eubacteria	BAC62311
<i>Enterococcus faecalis</i>	Eubacteria	AAO81155
<i>Lactobacillus johnsonii</i>	Eubacteria	AE017204
<i>Chloroflexus aurantiacus</i>	Eubacteria	AJ299212
<i>Enterococcus faecium</i>	Eubacteria	AF290094
<i>Listeria monocytogenes</i>	Eubacteria	AE017324
<i>Listeria innocua</i>	Eubacteria	CAC96053
<i>Streptococcus pneumoniae</i>	Eubacteria	AF290098
<i>Staphylococcus epidermidis</i>	Eubacteria	AF290090
<i>Staphylococcus haemolyticus</i>	Eubacteria	AF290088
<i>Staphylococcus aureus</i>	Eubacteria	AF290086
<i>Streptomyces griseolosporeus</i>	Eubacteria	AB037907
<i>Streptomyces</i> sp.	Eubacteria	AB015627
<i>Streptococcus pyogenes</i>	Eubacteria	AF290096
<i>Streptococcus mutans</i>	Eubacteria	AAN58647
<i>Paracoccus zeaxanthinifaciens</i>	Eubacteria	AJ431696
<i>Pseudomonas mevalonii</i>	Eubacteria	M24015
<i>Borrelia burgdorferi</i>	Eubacteria	AE001169
<i>Actinoplanes</i> sp.	Eubacteria	AB113568

*Common names are indicated in parentheses. Accession numbers for each sequence are available from sequence databases accessible through the National Center for Biotechnology Information [25].

that the stereospecificity of the HMGR_H hydrogen transfer is opposite to that of HMGR_P.

Comparisons between the HMGR_P and HMGR_H structures reveal an overall similarity in how they bind statins, which inhibit activity by blocking access of HMG-CoA to the active site. There is a considerable difference in specific interactions with inhibitor between the two enzymes, however [8,9], accounting for the almost 10⁴-fold higher *K_i* values for inhibition of HMGR_P by statin relative to the inhibition of HMGR_H (*K_i* is the equilibrium constant for an inhibitor binding to an enzyme). There are significant differences in the regions of the two proteins that bind statins. In both enzymes the portion of the statin that resembles HMG (see


Figure 3) occupies the HMG portion of the HMG-CoA-binding pocket, and the non-polar region partially occupies a portion of the coenzyme-A-binding site. For HMGR_p, this impairs closure over the active site of the 'tail' domain that contains the catalytic histidine.

Localization and function



HMGRs of eukaryotes are localized to the endoplasmic reticulum (ER), and are directed there by a short portion of the amino-terminal domain (prokaryotic HMGRs are soluble and cytoplasmic). In humans, the reaction catalyzed by HMGR is the rate-limiting step in the synthesis of cholesterol, which maintains membrane fluidity and serves as a precursor for steroid hormones. In plants, a cytosolic HMG-CoA reductase participates in the synthesis of sterols, which are important in plant defense mechanisms against herbivores, and ubiquinone, which is critical for cellular protein turnover. In plastids, however, these compounds are synthesized via a pathway that does not involve mevalonate or HMGR [1]. Various plant HMGR isozymes function in fruit ripening and in the response to environmental challenges such as attack by pathogens. In yeast, either of the two ER-anchored HMGR isozymes can provide the mevalonate needed for growth.

Enzyme mechanism

The reaction catalyzed by HMGR is:



with the (S)-HMG-CoA and (R)-mevalonate designations referring to the stereochemistry of the substrate and product (enzymatic reactions are stereospecific and the (R)-HMG-CoA isomer is not a substrate for HMGR). This three-stage reaction involves two reductive stages and the formation of enzyme-bound mevaldyl-CoA and mevaldehyde as probable intermediates:



Kinetic analysis of point mutants of HMGR_p and of HMGR_H, and inspection of the crystal structures of HMGR_p and HMGR_H, has identified an aspartate, a glutamate, a histidine, and a lysine that are likely to be important and have suggested their probable roles in catalysis (Figure 4) [11].

Regulation

A highly regulated enzyme, HMGR_H is subject to transcriptional, translational, and post-translational control [12] that can result in changes of over 200-fold in intracellular





Figure 3

Structures of lovastatin, a statin drug that competitively inhibits HMGR, and of HMG-CoA. It can be seen that the portion of the drug shown here at the top resembles the HMG portion of HMG-CoA.

levels of the enzyme. The transcription factor sterol regulatory element-binding protein 2 (SREBP-2) participates in regulating levels of HMGR_H mRNA in response to the level of sterols [13]; the regulatory process is as follows. At the ER membrane or the nuclear envelope, SREBP-2 binds to SREBP cleavage activating protein (SCAP) to form a SCAP-SREBP complex that functions as a sterol sensor. The proteins Insig-1 and Insig-2 bind to SCAP when cellular cholesterol levels are high and prevent movement of the SCAP-SREBP complex from the ER to the Golgi. In cells depleted of cholesterol, Insig-1 and Insig-2 allow activation of the SCAP-SREBP complex and its translocation to the Golgi, where SREBP is cleaved at two sites. Cleavage releases the amino-terminal basic helix-loop-helix (bHLH) domain, which enters the nucleus, where it functions as a transcription factor that recognizes non-palindromic decanucleotide sequences of DNA called sterol-regulatory elements (SREs). Binding of the bHLH domain of SREBP to an SRE promotes transcription of the *hmgr* gene.

Degradation of HMGR_H involves its transmembrane regions [14]: removal of two or more transmembrane regions abolishes the acceleration of HMGR_H degradation that occurs under certain conditions [12,15]: degradation is induced by a non-sterol, mevalonate-derived metabolite alone or by a sterol plus a mevalonate-derived non-sterol metabolite, possibly farnesyl pyrophosphate or farnesol. Four conserved phenylalanines in the sixth membrane span of the transmembrane region are essential for degradation of HMGR_H [16]. Insig-1 also functions in the degradation of HMGR_H [17]: when cholesterol levels are high, SCAP and HMGR_H compete for binding to Insig-1. If SCAP binds Insig-1, the SCAP-Insig-1 complex is retained in the Golgi, whereas if HMGR_H binds Insig-1, HMGR_H is ubiquitinated on lysine 248 and is rapidly degraded through a ubiquitin-proteasome mechanism [18].

**Figure 4**

Proposed reaction mechanism for HMGR_p [7,18]. The side groups of the key catalytic residues, Lys267, Asp283, Glu83, and His381, are shown, and the substrate and products are shown with R representing the HMG portion. The reaction follows three stages (see text for details). A basically similar mechanism has been proposed for HMGR_H [4].

The catalytic activity of the HMGRs of higher eukaryotes is attenuated by phosphorylation of a single serine, which in the case of HMGR_H is at position 872 [19]. The location of this serine - six residues from the catalytic histidine, a spacing conserved in all higher eukaryote HMGRs - suggests that the phosphoserine may interfere with the ability of this histidine to protonate the inhibitory CoA-S⁻ thioanion that is released in stage 2 of the reaction mechanism. Alternatively, it may interfere with closure of the flap domain, a carboxy-terminal region that is thought to close over the active site to facilitate catalysis, a step thought to be essential for formation of the active site [7]. Subsequent dephosphorylation restores full catalytic activity. HMGR kinase (also called AMP kinase) phosphorylates HMGR; the primary phosphatase *in vivo* is thought to be protein phosphatase 2A (PP2A), but both phosphatases 2A and 2B can catalyze dephosphorylation of vertebrate HMGR *in vitro* [20]. HMGR_H activity therefore responds to hormonal control through AMP levels and PP2A activity. Phosphorylation of serine 577 of *A. thaliana* HMGR isozyme 1 by a plant HMGR kinase that does not require 5'-AMP attenuates activity, and restoration of HMGR activity follows from dephosphorylation [21]. As many plant genes encode a putative target serine surrounded by an apparent AMP kinase recognition motif, it is probable that most plant HMGRs are regulated by phosphorylation. Yeast HMGR activity is, however, unaffected by AMP kinase. The phosphorylation state of HMGR does not affect the rate at which the protein is degraded.

Frontiers

Several basic unresolved questions concern how phosphorylation controls the catalytic activity of HMGRs; solution of the structures of phosphorylated HMGRs should reveal more of the precise mechanism. The protein kinases, phosphatases, and signal-transduction pathways that participate in short-term regulation of HMGR activity are yet to be elucidated. Finally, the physiological roles served by the multiple ways in which HMGR is regulated require clarification. On the medical side, continuing intense competition between drug companies for a share of the lucrative worldwide market for hypercholesterolemic agents should result in new statin drugs with modified pharmacodynamic and metabolic properties that not only lower plasma cholesterol levels more effectively but more importantly minimize undesirable side effects.

References

1. Laule O, Furholz A, Chang HS, Zhu T, Wang X, Heifetz PB, Gruissem W, Lange M: **Crosstalk between cytosolic and plastidial pathways of isoprenoid biosynthesis in *Arabidopsis thaliana***. *Proc Natl Acad Sci USA* 2003, **100**:6866-6871. A study of the regulation of both mevalonate and mevalonate independent pathways for isoprenoid synthesis in plants.
2. Bochar DA, Stauffacher CV, Rodwell VV: **Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase**. *Mol Genet Metab* 1999, **66**:122-127. This article reported the classification of HMG-CoA reductases into Class I and Class II enzymes on the basis of sequence comparison. The authors utilized phylogenetic analysis to analyze a plethora of genomic sequences of various organisms.
3. Hedl M, Taberner L, Stauffacher CV, Rodwell VV: **Class II 3-hydroxy-3-methylglutaryl coenzyme A reductases**. *J Bacteriol* 2004, **186**:1927-1932.

- A review article detailing current research and thought concerning Class II forms of the enzyme, including the HMGRs of many pathogenic bacteria.
4. Istvan ES, Palnitkar M, Buchanan SK, Deisenhofer J: **Crystal structure of the catalytic portion of human HMG-CoA reductase: insights into regulation of activity and catalysis.** *EMBO J* 2000, **19**:819-830.
This article and [5] reported the crystal structure of the human HMG-CoA reductase catalytic domain, providing numerous insights into catalysis by a Class I HMG-CoA reductase.
 5. Istvan ES, Deisenhofer J: **The structure of the catalytic portion of human HMG-CoA reductase.** *Biochim Biophys Acta* 2000, **1529**:9-18.
See [4].
 6. Lawrence CM, Rodwell VW, Stauffacher CV: **The crystal structure of *Pseudomonas mevalonii* HMG-CoA reductase at 3.0 Å resolution.** *Science* 1995, **268**:1758-1762.
This article reports the first HMG-CoA reductase structure that was solved.
 7. Tabernero LD, Bochar DA, Rodwell VW, Stauffacher CV: **Substrate-induced closure of the flap domain in the ternary complex structures provides new insights into the mechanism of catalysis by 3-hydroxy-3-methylglutaryl-CoA reductase.** *Proc Natl Acad Sci USA* 1999, **96**:7167-7171.
The original structure of *P. mevalonii* HMG-CoA reductase [6] lacked a portion of the enzyme known to be critical for catalysis. This article provided insight into the catalytic mechanism by solving the structure of the original missing region.
 8. Istvan ES, Deisenhofer J: **Structural mechanism for statin inhibition of HMG-CoA reductase.** *Science* 2001, **292**:1160-1164.
This article reports a structural explanation for inhibition of human HMG-CoA reductase by statins, which are widely prescribed drugs for hypercholesterolemia.
 9. Tabernero L, Rodwell VW, Stauffacher CV: **Crystal structure of a statin bound to a class II hydroxymethylglutaryl-CoA reductase.** *J Biol Chem* 2003, **278**:19933-19938.
The authors detail the interaction of *P. mevalonii* HMG-CoA reductase, a Class II enzyme, with statins.
 10. Istvan ES: **Bacterial and mammalian HMG-CoA reductases: related enzymes with distinct architectures.** *Curr Opin Struct Biol* 2001, **11**:746-751.
A review that provides insight into the relationships between Class I and Class II HMG-CoA reductases, both in terms of structure and evolution.
 11. Bochar DA, Friesen JA, Stauffacher CV, Rodwell VW: **Biosynthesis of mevalonic acid from acetyl-CoA.** In *Isoprenoids Including Carotenoids and Steroids*. Edited by Cane D. New York: Pergamon Press, 1999, 15-44.
A comprehensive review article detailing the catalysis, structure, and regulation of HMG-CoA reductase. It is written from the point of view of natural products synthesis.
 12. Goldstein JL, Brown MS: **Regulation of the mevalonate pathway.** *Nature* 1990, **343**:425-430.
The first major report on the regulation of HMG-CoA reductase.
 13. Horton JD, Goldstein JL, Brown MS: **SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.** *J Clin Invest* 2002, **109**:1125-1131.
A recent review detailing the role of sterol regulatory element binding proteins (SREBPs) in the regulation of cholesterol biosynthesis. This is the transcriptional control for HMG-CoA reductase.
 14. Mitropoulos KA, Venkatesan S: **Membrane-mediated control of HMG-CoA reductase activity.** In *Regulation of HMG-CoA Reductase*. Edited by Preiss B. Orlando: Academic Press, 1985, 1-48.
A classical review article summarizing the role of the membrane anchor domain in HMG-CoA reductase degradation.
 15. Jingami H, Brown MS, Goldstein JL, Anderson RJ, Luskey KL: **Partial deletion of membrane-bound domain of 3-hydroxy-3-methylglutaryl coenzyme A reductase eliminates sterol-enhanced degradation and prevents formation of crystalloid endoplasmic reticulum.** *J Cell Biol* 1987, **104**:1693-1704.
The original report of the sterol-mediated regulation of HMG-CoA reductase degradation and localization of the region responsible for mediating this degradation.
 16. Xu L, Simoni RD: **The inhibition of degradation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase by sterol regulatory element binding protein cleavage-activating protein requires four phenylalanine residues in span 6 of HMG-CoA reductase transmembrane domain.** *Arch Biochem Biophys* 2003, **414**:232-243.
A study of the structure-function relationships between HMG-CoA reductase degradation and the sterol cleavage activating protein (SCAP).
 17. Sever N, Yang T, Brown MS, Goldstein JL, DeBose-Boyd RA: **Accelerated degradation of HMG-CoA reductase mediated by binding of insig-I to its sterol-sensing domain.** *Mol Cell* 2003, **11**:25-33.
The authors identified the role of the protein insig-I in regulation of HMG-CoA reductase by degradation.
 18. Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA: **Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol.** *J Biol Chem* 2003, **278**:52479-52490.
This study described the relationship between ubiquitination, degradation, and the protein insig-I in HMG-CoA reductase degradation.
 19. Sato R, Goldstein JL, Brown MS: **Replacement of serine-871 of hamster 3-hydroxy-3-methylglutaryl-CoA reductase prevents phosphorylation by AMP-activated kinase and blocks inhibition of sterol synthesis induced by ATP depletion.** *Proc Natl Acad Sci USA* 1993, **90**:9261-9265.
In this study, the authors identified the specific amino acid of mammalian HMG-CoA reductase that is phosphorylated and mediates regulation of HMG-CoA reductase by reversible phosphorylation.
 20. Hardie DG: **The AMP-activated protein kinase cascade: the key sensor of cellular energy status.** *Endocrinology* 2003, **144**:5179-5183.
A review article describing the AMP-activated protein kinase (AMPK) that phosphorylates HMG-CoA reductase.
 21. Dale S, Arro M, Becerra B, Morrice NG, Hardie DG, Ferrer A: **Bacterial expression of the catalytic domain of 3-hydroxy-3-methylglutaryl-CoA reductase (isoform hmgrI) from *Arabidopsis thaliana*, and its inactivation by phosphorylation at Ser577 by *Brassica oleracea* 3-hydroxy-3-methylglutaryl-CoA reductase kinase.** *Eur J Biochem* 1995, **233**:506-513.
A study that illustrated that plant HMG-CoA reductases are probably regulated by reversible phosphorylation.
 22. **Ensembl Human Genome browser** [http://www.ensembl.org/Homo_sapiens/]
Ensembl information about the human HMG-CoA reductase gene and transcript details.
 23. Higgins D, Thompson J, Gibson T, Thompson JD, Higgins DG, Gibson TJ: **CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice.** *Nucleic Acids Res* 1994, **22**:4673-4680.
An article describing the CLUSTAL W program, which is used for multiple sequence alignments of amino-acid sequences.
 24. **TreeTop - Phylogenetic tree prediction** [http://www.genebee.msu.edu/services/phtree_reduced.html]
A program for phylogenetic tree generation.
 25. **National Center for Biotechnology Information** [<http://www.ncbi.nlm.nih.gov>]
The NCBI contains a vast amount of sequence information, including protein and nucleic acid sequences for HMG-CoA reductases and information on the sequencing of genomes of organisms containing HMG-CoA reductase isoforms.